83 related articles for article (PubMed ID: 8867894)
21. Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis.
Mizoguchi Y; Shin T; Sakagami Y; Seki S; Kuroki T; Kobayashi K; Yamamoto S; Morisawa S
Gastroenterol Jpn; 1988 Apr; 23(2):147-52. PubMed ID: 3260204
[TBL] [Abstract][Full Text] [Related]
22. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.
Palladino MA; Shalaby MR; Kramer SM; Ferraiolo BL; Baughman RA; Deleo AB; Crase D; Marafino B; Aggarwal BB; Figari IS
J Immunol; 1987 Jun; 138(11):4023-32. PubMed ID: 3295044
[TBL] [Abstract][Full Text] [Related]
24. Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice.
Castagne V; Bonhomme-Faivre L; Urien S; Ben Reguiga M; Soursac M; Gimenez F; Farinotti R
Drug Metab Dispos; 2004 Feb; 32(2):168-71. PubMed ID: 14744937
[TBL] [Abstract][Full Text] [Related]
25. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
[TBL] [Abstract][Full Text] [Related]
26. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of astaxanthin and its mode of action.
Jyonouchi H; Sun S; Iijima K; Gross MD
Nutr Cancer; 2000; 36(1):59-65. PubMed ID: 10798217
[TBL] [Abstract][Full Text] [Related]
28. Comparison of vascular leak syndrome in mice treated with IL21 or IL2.
Sivakumar PV; Garcia R; Waggie KS; Anderson-Haley M; Nelson A; Hughes SD
Comp Med; 2013 Feb; 63(1):13-21. PubMed ID: 23561933
[TBL] [Abstract][Full Text] [Related]
29. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma.
Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M
Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569
[TBL] [Abstract][Full Text] [Related]
30. Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice.
Veau C; Faivre L; Tardivel S; Soursac M; Banide H; Lacour B; Farinotti R
J Pharmacol Exp Ther; 2002 Aug; 302(2):742-50. PubMed ID: 12130739
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy with low-dose interleukin-2 and interferon-gamma in a murine tumor model.
Mao XW; Kettering JD; Gridley DS
J Interferon Cytokine Res; 1995 Dec; 15(12):1017-27. PubMed ID: 8746782
[TBL] [Abstract][Full Text] [Related]
32. Anti-tumor activity of recombinant tumor necrosis factor on mouse fibrosarcoma in vivo and in vitro.
Tomazic VJ; Farha M; Loftus A; Elias EG
J Immunol; 1988 Jun; 140(11):4056-61. PubMed ID: 3372997
[TBL] [Abstract][Full Text] [Related]
33. Ethanol consumption suppresses the IL2-induced proliferation of NK cells.
Gallucci RM; Meadows GG
Toxicol Appl Pharmacol; 1996 May; 138(1):90-7. PubMed ID: 8658518
[TBL] [Abstract][Full Text] [Related]
34. Synergistic effects between recombinant interleukin-2 and the synthetic immunomodulator murabutide: selective enhancement of cytokine release and potentiation of antitumor activity.
Bahr GM; Darcissac E; Pouillart PR; Chedid LA
J Interferon Cytokine Res; 1996 Feb; 16(2):169-78. PubMed ID: 8742370
[TBL] [Abstract][Full Text] [Related]
35. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts.
Nagata Y; Furugen R; Hiasa A; Ikeda H; Ohta N; Furukawa K; Nakamura H; Furukawa K; Kanematsu T; Shiku H
J Immunol; 1997 Aug; 159(3):1336-43. PubMed ID: 9233630
[TBL] [Abstract][Full Text] [Related]
36. Low doses of interleukin 2 induce bystander cell lysis by antigen-specific CD4+ inflammatory T cell clones in short-term assay.
Gromkowski SH; Hepler KM; Janeway CA
Eur J Immunol; 1988 Sep; 18(9):1385-9. PubMed ID: 2901965
[TBL] [Abstract][Full Text] [Related]
37. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
38. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
39. Enhancing effects of autologous erythrocytes on human or mouse cytokine secretion and IL-2R expression.
Kalechman Y; Herman S; Gafter U; Sredni B
Cell Immunol; 1993 Apr; 148(1):114-29. PubMed ID: 8098664
[TBL] [Abstract][Full Text] [Related]
40. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
Gambacorti-Passerini C; Rivoltini L; Supino R; Rodolfo M; Radrizzani M; Fossati G; Parmiani G
Cancer Res; 1988 May; 48(9):2372-6. PubMed ID: 3258541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
